The U.S. boasts the most innovative biopharmaceutical industry in the world. These companies deliver vital cures to patients and the majority of sales the industry make are made by domestic companies. But that global leadership in a critical industry was challenged in May 2025, when the Department of Commerce announced it was initiating an investigation […]
Americans are continually worried about the cost of healthcare. There are a plethora of good and bad ideas to make healthcare more affordable, including Most Favored Nation (MFN) price controls, which would import prices for pharmaceuticals from other countries, many of which rely on socialized medicine and government-run healthcare. But price controls in any industry, […]
Congress created the 340B program in 1992 to fix a problem it had created two years earlier when it implemented price controls, or rebates, in the Medicaid drug benefit program. As a condition to participate in Medicaid, pharmaceutical companies must also partake in the 340B program, giving significant discounts of between 20-50 percent, to certain federally-funded […]
February 3, 2026 Marty Makary Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Dear Commissioner Makary, Thank you for your ongoing work to ensure the safety and efficacy of pharmaceuticals for all Americans. We are grateful for your diligent enforcement of President Trump’s vision to […]
The United States is the global leader in developing innovative and life-saving cures and treatments thanks to the investments made by pharmaceutical companies in the United States, including the vaccines that helped end the coronavirus pandemic. Vaccines are crucial to the physical and economic health of not just Americans but also people across the rest […]
The 340B Drug Discount Program was given the laudable goal of helping federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. However, like many other well-intended federal programs 340B has gone off the rails due to the lack of clear intent and […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
Federal healthcare programs are often well-intended but end up costing more than expected and become subject to waste, fraud, abuse, and mismanagement. One of the best (or worst) examples of such a result is the 340B Drug Pricing Program, which is administered by the Health Resources and Services Administration (HRSA). The lack of clear intent […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
President Trump has made government efficiency a top priority. These efforts include eliminating improper payments and ensuring that only those who are eligible for government programs receive the benefits, including Medicaid. As President Trump said on “Meet the Press” on Sunday, May 4, 2025, “if illegal immigrants are in the mix, if people that aren’t […]
